FOR THOSE OF YOU waiting for a list of do's and don'ts from the Office of Inspector General in order to help you comply with the OIG's new pharmaceutical marketing guidance and avoid violating federal anti-kickback laws, don't hold your breath. “We probably never will provide such a list,” said Mary E. Riordan, senior counsel, OIG, speaking at the American Medical Association's 14th Annual Conference of the National Task Force on CME Provider/Industry Collaboration. Held September 8 to 11 ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the OIG and CME: No Easy Answers, you'll also gain access to exclusive premium content.

Already registered? here.